GLP Watchdog

Best Semax Providers in 2026 — Ranked & Reviewed

A fragment of ACTH is the origin of Semax, a synthetic peptide developed in Russia across the 1980s. Approval there, for cognitive dysfunction and stroke recovery, dates to 2011. A nasal spray is the usual route. Few known compounds stimulate BDNF (brain-derived neurotrophic factor) more potently, and that protein is central to neuron survival and plasticity. Russian trials have reported better neurological recovery where Semax is added to standard stroke care. Set against that: no US FDA approval for any use at all, no large-scale trials in the West, and no compounding pharmacy permitted to sell it here lawfully. The current status is below.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

Why nothing is ranked here yet

Semax was recommended for Section 503A's Bulk Drug Substances List on July 24, 2026 by the Pharmacy Compounding Advisory Committee (PCAC) at the FDA, on a vote of 8-5 with one abstention. A recommendation is all that is. Formal action by the FDA and HHS has to follow before any compounding pharmacy may lawfully sell Semax. We are tracking that decision, and a compliant provider will be ranked here the moment one exists.

Listing a provider that cannot legally sell this yet would be worse than listing nobody, so nothing is shown. The FDA’s decision is being tracked, and a compliant provider will be ranked here the moment one exists.

How we rank, and what counts as “legit”

Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.

Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].

How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Frequently Asked Questions

Sources & methodology — as of August 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings